重症心力衰竭患者血清CXCL16、sST2水平变化及其与预后的关系

doi:10.20047/j.issn1673-7210.2023.02.12

Abstract
Figure/Table
References (27)
Related Citation (15)

Download: PDF (638 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the relationship between serum C-X-C motif chemokine ligand 16 (CXCL16) and soluble suppression of tumorigenicity 2 (sST2) levels and the prognosis of patients with severe heart failure (SHF). Methods A total of 168 patients with SHF admitted to Nanchong Central Hospital from January 2020 to February 2021 were selected and they were divided into 41 cases in the death group and 127 cases in the survival group according to their prognosis. General information of patients was collected and serum CXCL16 and sST2 levels were measured by enzyme-linked immunosorbent assay. Multi-factor logistic regression was used to analyze the factors influencing death in SHF patients, and subject work characteristic curves were used to analyze the predictive value of serum CXCL16 and sST2 levels on death in SHF patients. Results The age of death group was longer than that of survival group, and the course of disease was longer than that of survival group. The New York Heart Association grade Ⅳ ratio, blood uric acid, B-type natriuretic peptide, CXCL16, and sST2 levels were higher than those of survival group, and systolic blood pressure and left ventricular ejection fraction were lower than those of survival group, with statistical significances (P＜0.05). Multivariate logistic regression analysis showed that disease duration, New York Heart Association grade, B-type natriuretic peptide, CXCL16, and sST2 were independent risk factors for death in patients with SHF, while systolic blood pressure and left ventricular ejection fraction were independent protective factors (P＜0.05). The area under the curve of the combined prediction of serum CXCL16 and sST2 was greater than that of serum CXCL16 and sST2 alone (P＜0.05). Conclusion Elevated serum CXCL16 and sST2 levels are independent risk factors for death within one year in SHF patients. Combined testing of serum CXCL16 and sST2 levels can enhance the predictive value of death in SHF patients.

Key words： Severe heart failure Inflammation C-X-C motif chemokine ligand 16 Soluble suppression of tumorigenicity 2 Prognosis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHAO Jinghong1 QIAO Yan2 ZHANG Rongyi1 DENG Jianping1 CHEN Yong1

Cite this article:

ZHAO Jinghong1 QIAO Yan2 ZHANG Rongyi1 DENG Jianping1 CHEN Yong1. Changes in serum CXCL16 and sST2 levels in patients with severe heart failure and the relationship with prognosis[J]. 中国医药导报, 2023, 20(2): 56-59.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2023.02.12 OR https://www.yiyaodaobao.com.cn/EN/Y2023/V20/I2/56

[1] Morris AA，Khazanie P，Drazner MH，et al. Guidance for Timely and Appropriate Referral of Patients With Advanced Heart Failure：A Scientific Statement From the American Heart Association [J]. Circulation，2021，144（15）：e238-e250.
[2] Schiattarella GG，Sequeira V，Ameri P. Distinctive patterns of inflammation across the heart failure syndrome[J]. Heart Fail Rev，2021，26（6）：1333-1344.
[3] Korbecki J，Bajdak-Rusinek K，Kupnicka P，et al. The Role of CXCL16 in the Pathogenesis of Cancer and Other Diseases [J]. Int J Mol Sci，2021，22（7）：3490.
[4] 曾艳，谭华清，唐湘宇，等.可溶性ST2与心血管疾病关系的研究进展[J].实用心脑肺血管病杂志，2019，27（5）：112-116.
[5] 王延博，林玲，李宇球，等.SDF-1、CXCL16水平在包含HFmrEF组的慢性心力衰竭患者中的变化[J].临床心血管病杂志，2018，34（3）：249-254.
[6] Lotierzo M，Dupuy AM，Kalmanovich E，et al. sST2 as a value-added biomarker in heart failure[J]. Clin Chim Acta，2020，501：120-130.
[7] 中华医学会心血管病学分会心力衰竭学组，中国医师协会心力衰竭专业委员会，中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志，2018，46（10）：760-789.
[8] McDonagh TA，Metra M，Adamo M，et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure [J]. Eur Heart J，2021，42（36）：3599-3726.
[9] 李娜，张羽，齐晓瑜，等.重症心力衰竭患者血清可溶性生长刺激表达基因2蛋白水平及意义[J].中华实用诊断与治疗杂志，2022，36（3）：259-262.
[10] 中国医疗保健国际交流促进会循证医学分会，海峡两岸医药卫生交流协会老年医学专业委员会.心力衰竭生物标志物中国专家共识[J].中华检验医学杂志，2020， 43（2）：130-141.
[11] Nakashima M，Sakuragi S，Miyoshi T，et al. Fibrosis-4 index reflects right ventricular function and prognosis in heart failure with preserved ejection fraction [J]. ESC Heart Fail，2021，8（3）：2240-2247.
[12] 刘誉，王素丹，罗苑苑，等.血清FT3、cTnI、BNP对老年急性心力衰竭患者危险分层和预后预测的应用价值比较[J].中国医药导报，2021，18（26）：54-59.
[13] Hanna A，Frangogiannis NG. Inflammatory Cytokines and Chemokines as Therapeutic Targets in Heart Failure[J]. Cardiovasc Drugs Ther，2020，34（6）：849-863.
[14] 常贵珍，张理涛.CXCL16与银屑病研究进展[J].国际免疫学杂志，2019，42（2）：208-213.
[15] Turgunova LG，Shalygina AA，Zalkalns JP，et al. Assessment of Adipokines，CXCL16 Chemokine Levels in Patients With Rheumatoid Arthritis Combined With Metabolic Syndrome [J]. Clin Med Insights Arthritis Musculoskelet Disord，2021，14：1179544120985860.
[16] Liang FQ，Gao JY，Liu JW. C-X-C motif chemokine 16，modulated by microRNA-545，aggravates myocardial damage and affects the inflammatory responses in myocardial infarction [J]. Hum Genomics，2021，15（1）：15.
[17] Zhao G，Zhang H，Zhu S，et al. Interleukin-18 accelerates cardiac inflammation and dysfunction during ischemia/ reperfusion injury by transcriptional activation of CXCL16 [J]. Cell Signal，2021，87：110141.
[18] Wang S，Ma L，Yang J，et al. Activation of CXCL16/CXCR6 axis aggravates cardiac ischemia/reperfusion injury by recruiting the IL-17a-producing CD1d+ T cells [J]. Clin Transl Med，2021，11（2）：e301.
[19] 王宙，王天娇，芦中林，等.可溶性生长刺激表达基因 2 蛋白在急性心肌梗死中的研究进展[J].国际心血管病杂志，2019，46（5）：281-284.
[20] 黄水珍，韦青春，支馨仪，等.血清sST2在心力衰竭诊断、预后中的应用价值[J].生物工程学报，2020，36（9）：1713-1722.
[21] Chen WY，Wu YH，Tsai TH，et al. Group 2 innate lymphoid cells contribute to IL-33-mediated alleviation of cardiac fibrosis [J]. Theranostics，2021，11（6）：2594-2611.
[22] 林春尧，刘晓辉.IL-33/ST2在冠心病中的研究进展[J].心血管病学进展，2020，41（2）：128-131.
[23] Homsak E，Gruson D. Soluble ST2： A complex and diverse role in several diseases [J]. Clin Chim Acta，2020，507：75- 87.
[24] 崔雪飞.可溶性ST2在心力衰竭中的研究进展[J].海南医学，2020，31（21）：2800-2803.
[25] 郭晓，王肖龙，汤仁智，等.可溶性基质裂解素2和脑利钠肽对射血分数保留型心力衰竭诊断的临床意义[J].中国医药导报，2020，17（15）：29-33.
[26] 孙芸，张婷婷，张燚.血浆sST2联合NT-proBNP对急诊心力衰竭患者生存状况的预测价值[J].临床和实验医学杂志，2020，19（8）：849-852.
[27] Grand J，Miger K，Sajadieh A，et al. Systolic Blood Pressure and Outcome in Patients Admitted With Acute Heart Failure：An Analysis of Individual Patient Data From 4 Randomized Clinical Trials [J]. J Am Heart Assoc，2021，10（18）：e022288.